Twenty-five year evolution of medical hormonal therapy for prostate cancer.
Moul
Judd W
JW
Division of Urologic Surgery, Department of Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA. judd.moul@duke.edu
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D018931:Antineoplastic Agents, Hormonal; D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen; D016729:Leuprolide